TB CAB, TAG open letter to Cepheid

By TB CAB, Treatment Action Group
Published: Jan. 8, 2014, 3:53 p.m.· Tags: Advocacy, Diagnostics, TB CAB

Re: GeneXpert machine and Xpert MTB/RIF cartridge pricing, extended warranties and business in Russia and the People’s Republic of China

Read More →

TB CAB, CRAG, TAG open letter to Otsuka

By TB CAB, Community Research Advisors Group (CRAG), Treatment Action Group
Published: Dec. 5, 2013, 11:25 p.m.· Tags: None

Re: Urgent appeal to initiate delamanid compassionate use program

Read More →

TAG, TB CAB open letter to Alere

By Treatment Action Group, TB CAB
Published: Aug. 7, 2013, 8:03 p.m.· Tags: None

Re: Responsible marketing and access plans for Alere’s Determine TB-LAM antigen test for active TB

Read More →

TAG, TB CAB open letter to Sequella

By Treatment Action Group, TB CAB
Published: July 23, 2013, 7:28 p.m.· Tags: None

Re: Further research into sutezolid urgently needed for tuberculosis

Read More →

TAG, TB CAB, India CAB open letter to Immunoshop

By Treatment Action Group, TB CAB, India CAB
Published: July 3, 2013, 10:56 a.m.· Tags: None

Re: Marketing and use of TB Platinum for active TB in India and high TB burden countries

Read More →

TAG, TB CAB, India CAB open letter to Qiagen

By Treatment Action Group, TB CAB, India CAB
Published: May 17, 2013, 4:36 p.m.· Tags: None

Re: Marketing and use of QuantiFERON-TB Gold for active TB in India and high TB burden countries

Read More →

TB CAB open letters on EU-India FTA

By TB CAB
Published: April 24, 2013, 3:41 p.m.· Tags: None

Open letters to Indian Prime Minister and Health Minister to support India’s refusal of any Trade-Related Aspects of Intellectual Property Rights (TRIPS)-Plus Provisions in Free-Trade Agreement negotiations with the European Union.

Read More →

TB CAB: Open letter to the European Medicines Agency

By TB CAB
Published: March 19, 2013, 10:50 p.m.· Tags: None

Open letter to the European Medicines Agency regarding the filing of the drugs delamanid and bedaquiline for market approval.

Read More →

TB CAB, TAG open letter to Janssen regarding the FDA approval of bedaquiline

By TB CAB, Treatment Action Group
Published: March 15, 2013, 6:09 p.m.· Tags: Advocacy, Access

Determining a fair and affordable price of bedaquiline is essential for timely approval and appropriate domestic and global access to the best possible therapeutic options for people with DR-TB.

Read More →

Round table discussion: Activist engagement and community involvement in TB research

By TB CAB, Treatment Action Group
Published: June 12, 2012, 8:38 p.m.· Tags: None

3rd Annual South African TB Conference, Durban 2012
Date: 14 June 2012
Time: 14h00 – 15h30
Location: Hall 3B

Read More →